Please login to the form below

Not currently logged in
Email:
Password:

allergy

This page shows the latest allergy news and features for those working in and with pharma, biotech and healthcare.

Aimmune gets FDA panel backing for peanut allergy therapy

Aimmune gets FDA panel backing for peanut allergy therapy

Step closer to becoming first approved treatment. Aimmune’s AR101 has moved a step closer to becoming the first approved peanut allergy treatment in the US after an FDA advisory committee ... Peanut allergies are the leading cause of death from

Latest news

More from news
Approximately 15 fully matching, plus 182 partially matching documents found.

Latest Intelligence

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    Forecast sales for Skyrizi in 2023 are $1.74bn. AR-101 from Aimmune Therapeutics addresses peanut allergy.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    conditions. 2. AR101 – the first peanut allergy treatment. Potentially deadly allergies to food and other everyday substances are on the rise around the world – and there are currently very few therapies ... There are more than 1.5 million peanut

  • Asthma: beyond the blue and the brown Asthma: beyond the blue and the brown

    for prevention of cat and ragweed allergies.

  • Deal Watch July 2016 Deal Watch July 2016

    And Finally, Reality Bites. ALK-Abello has issued a press release announcing that Merck &Co has walked away from the deal agreed in 2007 (with Schering-Plough) for the allergy treatments ... Grastek and Ragwitek are sublingual allergy immunotherapy (SLIT)

  • Allergies and asthma Allergies and asthma

    The safest way to manage allergy symptoms is to tackle them before they set in. ... of the hypo-allergenic milk formula on cow's milk allergy and atopic dermatitis (AD).

More from intelligence
Approximately 1 fully matching, plus 18 partially matching documents found.

Latest appointments

  • ALK-Abello appoints Søren Jelert as CFO ALK-Abello appoints Søren Jelert as CFO

    He will be based at the company’s headquarters in Denmark. Dansih allergy immunotherapy company ALK-Abello has appointed Søren Jelert as its new chief financial officer, a role that sees ... to become a truly global allergy company.”.

  • Cytovation expands management team Cytovation expands management team

    Grego is currently chief executive officer of Spire Bioventures, a global healthcare consultancy and mentoring service, and has previously held a number of management positions at Spanish allergy specialist Laboratorios LETI.

  • Lars Dreiøe joins Sobi in senior quality and compliance role Lars Dreiøe joins Sobi in senior quality and compliance role

    He will join the firm in January from Danish allergy vaccine company ALK Abelló, where he was international head of quality.

  • ARC names chairman and member of the board ARC names chairman and member of the board

    ARC is a privately held biopharma company developing desensitisation treatments for food allergies. ... Iwicki said: “ARC is working to address a very compelling therapeutic area and provide an option to those dealing with food allergies.

  • Insmed appoints FDA's Dr Eugene Sullivan Insmed appoints FDA's Dr Eugene Sullivan

    He also spent a seven-year spell from 1999 at the FDA, where he held several positions, including deputy director of its Pulmonary and Allergy Products division.

More from appointments
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...
The era of digital wellbeing
Social media - friend or foe?...

Infographics